title: Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
abstract: In the spleen, exogenous antigen is preferentially presented by CD8alpha+CD11b- DC to CD8 T cells and by CD8alpha-CD11b+ DC to CD4 T cells. However, it is not yet clear whether the same rule applies to other secondary lymphoid organs. To address this issue, we first classified secondary lymphoid tissues into three categories based on the expression pattern of CD8alpha and CD11b in C57BL/6 and BALB/c mice: (a) spleen, (b) mesenteric lymph node (MLN) and (c) other peripheral lymph nodes (PLN). We then analyzed the OVA-specific T cell-stimulating capacity of each DC subset after intravenous injection with soluble OVA. Our results show that, regardless of tissue origin, CD8alpha-CD11b+ DC generally present OVA to CD4 T cells, a finding that held true as well for CD8alpha+CD11b+ DC in PLN. In striking contrast, CD8alpha+CD11b- DC in spleen, CD8alpha-CD11b+ DC in MLN and CD8alpha+CD11b+ DC in PLN mainly cross-present OVA to CD8 T cells in their respective tissues. Of note, CD8alpha-CD11b+ DC in MLN and CD8alpha+CD11b+ DC in PLN present OVA to both CD4 T and CD8 T cells. Therefore, the antigen-presenting capacity of each distinct DC subset is determined by its anatomic environment in combination with its surface phenotype.
authors.affiliation: Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea.
authors.forename: Yeonseok
authors.initials: Y
authors.lastname: Chung
authors.forename: Jae-Hoon
authors.initials: JH
authors.lastname: Chang
authors.forename: Byung-Seok
authors.initials: BS
authors.lastname: Kim
authors.forename: Jung-Mi
authors.initials: JM
authors.lastname: Lee
authors.forename: Ho-Youn
authors.initials: HY
authors.lastname: Kim
authors.forename: Chang-Yuil
authors.initials: CY
authors.lastname: Kang
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology; D039481:CD11b Antigen / Q000032:analysis; D039521:CD11c Antigen / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D016827:CD8 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D045142:Cross-Priming / Q000276:immunology; D003713:Dendritic Cells / Q000737:chemistry / Q000166:cytology / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007275:Injections, Intravenous; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008643:Mesentery / Q000166:cytology / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology
chemical_list: D000941:Antigens; D039481:CD11b Antigen; D039521:CD11c Antigen; D016827:CD8 Antigens; C431698:CD8alpha antigen; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D011948:Receptors, Antigen, T-Cell; D010047:Ovalbumin